Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous bimagrumab in overweight and obese patients with type 2 diabetes
2016-004124-26Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM), obesity and Overweight comparing Bimagrumab with Placebo (2 arms). Primary endpoint: Change in total body fat mass at week 48. Started Jul 2017; status: completed.
02
Drugs
bimagrumab
03
Conditions
type 2 diabetes mellitus (T2DM)obesityOverweight
Beyond the preview
Go deeper on 2016-004124-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004124-26.